A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

Completed · Phase 2 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus

In brief

This study will be conducted to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of anifrolumab given via the subcutaneous (SC) route of administration in adult Systemic Lupus Erythematosus (SLE) subjects with a type I Interferon (IFN) test high result and active skin manifestations while receiving Standard of Care (SOC) treatment. In addition, the efficacy of anifrolumab on SLE skin manifestations will be characterized.

Key facts

Study ID

NCT02962960

Run by

AstraZeneca

People needed

36

Starts

2017-02-14

Expected to finish

2018-12-17

Last updated by the study team

2023-01-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 through 70 years
• Diagnosis of paediatric or adult SLE for > 24 weeks and fulfilling ≥4 of the 11 American College of Rheumatology (ACR) classification criteria with at least one being:
• Positive antinuclear antibody (ANA) or
• Elevated anti-dsDNA antibodies or
• anti-Smith (anti-Sm) antibodies
• Interferon high test result
• Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score ≥ 10
• Currently receiving at least 1 of the following for treatment of SLE:
• Oral prednisone or equivalent of ≤40 mg/day for a minimum of 2 weeks prior to signing the Informed Consent Form (ICF) and with stable dose for at least 2 weeks prior to randomization
• Any of the following medications for at least 12 weeks prior to signing the ICF, and at a stable doses for at least 8 weeks prior to randomization: (i) Azathioprine ≤200 mg/day (ii) Antimalarials (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day
• Must not have signs of active or latent tuberculosis (TB).
• Must not be pregnant or breastfeeding.

You may not qualify if…

• Active severe or unstable neuropsychiatric SLE
• Active severe SLE-driven renal disease
• Any severe herpes infection at any time
• Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV infection.
• Known history of a primary immunodeficiency (splenectomy, or any underlying condition predisposing for infection
• Receipt of any investigation product within 4 weeks or 5 half -lives prior to signing of the ICF
• History of cancer, apart from:
• Squamous or basal cell carcinoma of the skin if successfully treated.
• Cervical cancer in situ if successfully treated

Where it is running

• Research Site — Thousand Oaks, California, United States
• Research Site — Orlando, Florida, United States
• Research Site — New York, New York, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Memphis, Tennessee, United States
• Research Site — Houston, Texas, United States
• Research Site — Debrecen, Hungary
• Research Site — Zalaegerszeg, Hungary
• Research Site — Bydgoszcz, Poland
• Research Site — Warsaw, Poland
• Research Site — Anyang-si, South Korea
• Research Site — Busan, South Korea
• Research Site — Daegu, South Korea
• Research Site — Gwangju, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.